All In Biotech

Drug Trial Radar · NCT06819514

The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease

A Phase 1/2, Multicenter, Open-label,Dose-escalation Study to Evaluate the Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease

Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Mar 1, 2025

Primary completion

Mar 15, 2028

Study completion Mar 15, 2028

Sponsor

Lead sponsor
Guangzhou Jiayin Biotech LtdIndustry
Sponsor type
Industry
First posted
Feb 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 1/2, multicenter, open-label, Dose-escalation study to evaluate the safety and efficacy of intravenous EXG110 in patients with Fabry disease

Conditions

  • Fabry Disease

Interventions

  • EXG110 InjectionDrug

    EXG110 Injection is gene therapy for Fabry Disease , uses a proprietary AAV capsid with improved liver and muscle specificity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: To evaluate the safety and tolerability of EXG110 following a single intravenous infusionTime frame: 52 weeks
  2. Phase 2: The changes from the baseline of kidney functionTime frame: 6 months
  3. Phase 2: The changes from the baseline of cardiac functionTime frame: 6 months
  4. Phase 2: The changes from the baseline of painTime frame: 6 months
  5. Phase 2: The changes from the baseline of gastrointestinal functionTime frame: 6 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • General Hospital of Eastern Theater Command

    Nanjing, Jiangsu, China

  • Children's Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • First Affiliated Hospital of Zhejiang University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.